XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Oct. 14, 2021
Oct. 02, 2021
Jun. 21, 2021
May 12, 2018
Apr. 30, 2021
Mar. 31, 2021
Jan. 31, 2020
Sep. 30, 2021
Jun. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Number of stock options granted [1]                    
Number of stock options exercised                    
Proceeds from exercise of stock options                   $ 4,999
Stock options exercise price [1]                    
Offering scenario, description                   A relative weighting of 75% - 97.5% was applied to the IPO scenario and 25% - 2.5% was assigned to the stay private scenario.  
Weighted average fair value of stock options               $ 4.19   $ 4.19  
Expected term of stock options (in years)               5 years 8 months 12 days   5 years 8 months 12 days  
Expected stock price volatility               75.00%   75.00%  
Risk free interest rate               1.00%   1.00%  
Expected dividend yield               0.00%   0.00%  
2018 Equity Plan [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Common Stock, Capital Shares Reserved for Future Issuance               5,644,000   5,644,000  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant               3,104,200   3,104,200  
Number of stock options granted                   423,300  
Number of stock options exercised             4,703        
Proceeds from exercise of stock options             $ 4,999        
2018 Equity Plan [Member] | Restricted Stock Units (RSUs) [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Number of restricted stock awards granted         91,715 1,467,440       1,813,135  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding         $ 1,200,000 $ 18,900,000          
2018 Equity Plan [Member] | Restricted Stock Units (RSUs) [Member] | Director [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Number of restricted stock awards granted               253,980      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding               $ 3,400,000   $ 3,400,000  
2018 Equity Plan [Member] | Restricted Stock Units (RSUs) [Member] | Director [Member] | Share-based Payment Arrangement, Tranche One [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Number of restricted stock awards granted               169,320      
2018 Equity Plan [Member] | Restricted Stock Units (RSUs) [Member] | Director [Member] | Share-based Payment Arrangement, Tranche Two [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Number of restricted stock awards granted               84,660      
2018 Equity Plan [Member] | Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Number of restricted stock awards forfeited   7,055                  
2018 Equity Plan [Member] | Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member] | Director [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Number of restricted stock awards granted 84,660                    
2018 Equity Plan [Member] | Restricted Stock Units (RSUs) [Member] | Selling, General and Administrative Expenses [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Stock-based compensation expense                   1,100,000  
2018 Equity Plan [Member] | Restricted Stock Units (RSUs) [Member] | Research and Development Expense [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Stock-based compensation expense                   $ 100,000  
2018 Equity Plan [Member] | Investor [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Number of stock options granted       141,100              
Stock options exercise price       $ 0.35              
Stock options, vesting description       vesting ratably on a quarterly basis commencing June 30, 2018 and ending March 31, 2021              
Stock options, vesting term       10 years              
2014 Equity Plan [Member] | PAVmed Inc. [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures       25,000              
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price       $ 1.59              
Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term       10 years              
2014 Equity Plan [Member] | Lucid Diagnostics Inc [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures     50,000                
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price     $ 6.41                
[1] Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter, and have a ten-year contractual term from date-of-grant.